Roman Butler Fullerton & Co. Acquires New Shares in Axon Enterprise, Inc $AXON

Key Points

• Roman Butler Fullerton & Co. acquired a new stake in Axon Enterprise, Inc, purchasing 605 shares valued at approximately $501,000 during the second quarter.
• Several institutional investors, including Vanguard Group Inc. and Alliancebernstein L.P., have increased their stakes in Axon Enterprise, indicating strong interest in the company's stock.
• Axon Enterprise reported earnings of $2.12 per share for the last quarter, exceeding estimates and showcasing a 32.6% revenue increase compared to the previous year.

Roman Butler Fullerton & Co. bought a new stake in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 605 shares of the biotechnology company's stock, valued at approximately $501,000.

Several other hedge funds and other institutional investors also recently modified their holdings of AXON. Vanguard Group Inc. lifted its position in Axon Enterprise by 2.2% in the 1st quarter. Vanguard Group Inc. now owns 8,632,008 shares of the biotechnology company's stock valued at $4,540,005,000 after purchasing an additional 185,571 shares during the last quarter. Alliancebernstein L.P. increased its stake in shares of Axon Enterprise by 15.9% in the first quarter. Alliancebernstein L.P. now owns 1,284,935 shares of the biotechnology company's stock valued at $675,812,000 after purchasing an additional 175,890 shares during the period. Westfield Capital Management Co. LP increased its stake in shares of Axon Enterprise by 29.8% in the first quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company's stock valued at $487,977,000 after purchasing an additional 212,931 shares during the period. Northern Trust Corp raised its holdings in shares of Axon Enterprise by 1.2% during the first quarter. Northern Trust Corp now owns 725,720 shares of the biotechnology company's stock valued at $381,692,000 after buying an additional 8,794 shares during the last quarter. Finally, Jennison Associates LLC boosted its position in shares of Axon Enterprise by 23,203.7% during the first quarter. Jennison Associates LLC now owns 614,053 shares of the biotechnology company's stock worth $322,961,000 after buying an additional 611,418 shares during the period. Institutional investors and hedge funds own 79.08% of the company's stock.

Insider Buying and Selling at Axon Enterprise

In related news, CEO Patrick W. Smith sold 10,000 shares of the stock in a transaction on Tuesday, October 7th. The stock was sold at an average price of $713.74, for a total value of $7,137,400.00. Following the completion of the transaction, the chief executive officer owned 3,033,982 shares in the company, valued at $2,165,474,312.68. This trade represents a 0.33% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, President Joshua Isner sold 15,919 shares of the business's stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $746.26, for a total value of $11,879,712.94. Following the sale, the president owned 238,379 shares in the company, valued at approximately $177,892,712.54. The trade was a 6.26% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 59,932 shares of company stock valued at $45,115,616 over the last 90 days. 4.40% of the stock is owned by insiders.

Axon Enterprise Trading Down 0.8%

Axon Enterprise stock opened at $701.09 on Thursday. The firm has a market cap of $55.04 billion, a price-to-earnings ratio of 173.11, a price-to-earnings-growth ratio of 27.46 and a beta of 1.41. Axon Enterprise, Inc has a 1 year low of $422.38 and a 1 year high of $885.91. The firm's 50 day moving average price is $734.21 and its two-hundred day moving average price is $720.68. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.71 and a current ratio of 2.95.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The biotechnology company reported $2.12 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.58. The business had revenue of $668.54 million during the quarter, compared to analyst estimates of $641.77 million. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The company's revenue was up 32.6% compared to the same quarter last year. During the same period last year, the company posted $1.20 EPS. Axon Enterprise has set its FY 2025 guidance at EPS. On average, research analysts predict that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Wall Street Analyst Weigh In

AXON has been the subject of a number of analyst reports. Weiss Ratings reiterated a "hold (c)" rating on shares of Axon Enterprise in a research report on Wednesday, October 8th. Raymond James Financial reissued an "outperform" rating and set a $855.00 price target (up from $645.00) on shares of Axon Enterprise in a report on Tuesday, August 5th. Piper Sandler started coverage on shares of Axon Enterprise in a report on Tuesday, September 23rd. They issued an "overweight" rating and a $893.00 price objective for the company. Bank of America raised their target price on shares of Axon Enterprise from $895.00 to $1,000.00 and gave the company a "buy" rating in a research note on Wednesday, August 6th. Finally, JMP Securities reaffirmed a "market outperform" rating and issued a $825.00 price target on shares of Axon Enterprise in a research note on Monday, September 29th. Fourteen analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $841.64.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc (NASDAQ:AXON - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.